Ketim Technologies Showcases Biomarker-Driven Innovation at AusMedTech 2025 BioInnovation Spotlight

Sydney, Australia – May 8, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, was proud to present at the BioInnovation Spotlight during AusMedTech 2025, Australia’s premier medical technology conference hosted by AusBiotech.

Selected as part of this year’s cohort, Ketim Technologies pitched its cutting-edge, biomarker-driven and AI-powered solution for the early detection of postpartum depression (PPD) to an audience of industry leaders, investors, TGA representatives, and global medtech innovators. The presentation formed part of the conference’s theme, Innovation to Impact, highlighting transformative technologies with the potential to deliver life-changing outcomes.

The company’s approach combines a patented plasma protein biomarker panel with advanced AI/ML analytics to create the world’s first clinical blood test for predicting PPD during pregnancy — enabling intervention before symptoms arise.

“Presenting our work on such a prominent stage was both exciting and energising,” said Dr. Clarissa Yates, CEO and Founder of Ketim Technologies. “The connections, insights, and opportunities that emerged from AusMedTech will accelerate our pathway from innovation to real-world impact.”

The BioInnovation Spotlight opportunity was supported by the Department of Industry, Science and Resources through the Industry Growth Program, enabling Ketim Technologies to share its mission with a national and international audience.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au